DSMB recommends fourth continuation of Phase III BETonMACE trial of apabetalone

Resverlogix Corp. (TSX:RVX) said an independent DSMB recommended for the fourth time continuation of the double-blind, placebo-controlled, international Phase III BETonMACE trial evaluating twice-daily 100 mg apabetalone (RVX000222, RVX-208) with high-dose statin therapy in patients with coronary artery disease (CAD) and Type II diabetes.

The trial has enrolled about 1,600 of a planned 2,400 patients, with enrollment slated to be completed this fall...